With cars, computer and telecommunications irrevocably intertwined in the hyper connected 21st century, it is good to see Daimler and Nokia making pea.
Energy Heating, LLC ("Energy Heating") sued Heat On-The-Fly ("HOTF") and Super Heaters North Dakota ("SHND") in the District of North Dakota seeking a declaratory judgment.
An
inter partes review (IPR) before the Patent Trial
and Appeal Board (PTAB) is a proceeding of the petitioner versus
the patent owner. In a situation where the petitioner or the
patent owner consists of multiple entities, there may be a question
as to which entity may speak for the group. This is the issue
that the PTAB addressed in
The petitioner in this case is a group of 12 entities, including
well-known names such as Dell and Honeywell. In the petition
filed, these 12 entities are organized into seven groups, with a
different lead counsel designate for each group. Under this
Daimler to pay Nokia patent fees, ending legal fight Toggle share menu
Advertisement
Daimler to pay Nokia patent fees, ending legal fight Daimler has agreed to pay Nokia for using its patents, ending a row that highlighted a battle between tech and car companies over royalties for key technologies.
FILE PHOTO: The Daimler logo is seen before the Daimler annual shareholder meeting in Berlin, Germany, April 5, 2018. REUTERS/Hannibal Hanschke/File Photo
01 Jun 2021 02:10PM (Updated:
01 Jun 2021 02:10PM) Share this content
Bookmark
BRUSSELS: Daimler has agreed to pay Nokia for using its patents, ending a row that highlighted a battle between tech and car companies over royalties for key technologies.
Jun 01 2021
Opposition to a second Japanese patent, applied for in relation to the use of CRISPR methods in cellular studies, has been rejected by the Japanese Patent Office (JPO), reports ERS Genomics, the Dublin-based company providing access to this technology.
“The JPO actions reinforce the broad and fundamental nature of our CRISPR patent portfolio, both in Japan and worldwide.” Michael Arciero
Japanese patent (JP6692856), filed by CRISPR/Cas9 intellectual property co-owner Dr. Emannuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), covers compositions and methods for use in a variety of eukaryotic cells, in either dual-guide or single-guide format.